Lundbeck, a global drugmaker based in Denmark, has agreed to buy La Jolla-based Longboard Pharmaceuticals for $2.6 billion to ...

Fintel reports that on October 15, 2024, HC Wainwright & Co. downgraded their outlook for Longboard Pharmaceuticals (NasdaqGM ...

The Danish pharmaceutical company, with its US headquarters in Deerfield, is boosting its drug pipeline for serious brain ...

In a report released today, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on Longboard Pharmaceuticals (LBPH – Research ...

Lundbeck’s acquisition of Longboard Pharmaceuticals is meant to bolster its neuro-rare disease franchise, the drugmaker ...

Lundbeck, a biopharmaceutical company based in Denmark, has announced the acquisition of Longboard Pharmaceuticals in a ...

Fintel reports that on October 15, 2024, Truist Securities downgraded their outlook for Longboard Pharmaceuticals (NasdaqGM:LBPH) from Buy to Hold. Analyst Price Forecast Suggests 13.90% Upside As of ...

Longboard Pharmaceuticals is being acquired by Lundbeck for $60 per share, valuing the deal at $2.6 billion. Read more on ...

Just in the first half of 2024, over $1.7 billion was committed to autoimmune disease research. The influx is driven largely ...

On Monday, Longboard Pharmaceuticals Inc (LBPH) stock saw a modest uptick, ending the day at $58.99 which represents a slight increase of $20.09 or 51.65% from the prior close of $38.9. The stock ...

Lundbeck to buy clinical-stage biopharma company, Longboard Pharmaceuticals for USD 2.6 billion: Valby, Denmark Tuesday, October 15, 2024, 15:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

Lundbeck is to acquire Longboard for $2.6bn equity value in a move set to enhance its capabilities within neuro-rare ...